Search results :

Ondansetron

More information: STITCH, PubChem and possibly Wikipedia

ATC Code: A04AA01

Side effects

Options: Show MedDRA Preferred Terms,   display all 38 labels

Side effect Data for drug Placebo Labels
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Wound 10.6% - 27.6% 11.8% - 30.5% x x x x x x x
Drowsiness 5.43% - 20.4% 6.76% - 23% x x x x x x x x x x x x x
Headache very common, 5.83% - 27.2% 5.08% - 15% x x x x x x x x x x x x x x x x x x x x
Musculoskeletal pain 10.4% 10.8% x
Fatigue 2.29% - 13.2% 2.29% - 5.48% x x x x x x
Malaise 2.29% - 13.2% 2.29% - 5.48% x x x x x x
Hypoxia 8.91% 6.59% x x x x x x
Body temperature increased 1.83% - 8.18% 1.1% - 6.4% x x x x x x x x x x x x x x x
Genital disorder female 6.55% 6.21% x x x x x
Constipation common, 0.382% - 9.09% 0.382% x x x x x x x x x x x x x x x x x x x x
Anxiety 2.01% - 6.49% 2.93% - 6.43% x x x x x x x x
Agitation 2.01% - 6.49% 2.93% - 6.43% x x x x x x x
Bradycardia postmarketing — 5.82% 5.65% x x x x x x x x x x x x x x x x x
Dizziness postmarketing — 0.01% - 12.2% 4.58% - 16.1% x x x x x x x x x x x x x x x x x
Shivering 5.09% - 6.95% 5.65% - 7.13% x x x x x x x
Urinary retention 3.11% - 5.09% 2.74% - 3.39% x x x x x x x
Dry mouth common x x x x
Burning rectal common
Sensation of warmth common x x
Hypotension postmarketing — 1.83% - 4.91% 2.19% - 6.03% x x x x x x x x x x x x x x x x x x x x
Pruritus 1.65% - 4.91% 0.548% - 3.77% x x x x x x x x x x x x x
Diarrhoea 1.79% - 44% 0.898% - 18% x x x x x x x x x x x x x x x
Injection site reaction common, 3.84% 3.29% x x x x x x x x x
Chest pain postmarketing — 2.19% 2.74% x x x x x x x x x x x x x x x x x x x x
Dysuria 2.01% 1.65% x x
Paraesthesia 1.65% 0.366% x x x x x x x
Feeling cold 1.65% 1.46% x x x x x x x
Post procedural pain 1.19% 1.8% x
Dyskinesia uncommon x x x x
Movement disorder uncommon x x x x
Convulsion uncommon x x x x x
Warmth 1% x x x
Raised liver function tests postmarketing, uncommon x x x x
Anaphylactic shock postmarketing, rare x x x x x x x x x x x x x x x
Angina pectoris postmarketing x x x x x x x x x x x x x x x x x x
Angioedema postmarketing x x x x x x x x x x x x x x x x x
Arrhythmia postmarketing, uncommon x x x x x x x x x x x x x
Atrial fibrillation postmarketing x x x x x x x x x x x
Bronchospasm postmarketing, 0.595% 1.8% x x x x x x x x x x x x x x x x x x
Neoplasm malignant postmarketing x x x
Cardiovascular disorder postmarketing x x x
Dyspnoea postmarketing x x x x x x x x x x x x x x
Toxic epidermal necrolysis very rare, postmarketing x x x x x
Eye disorder postmarketing x x x x x x x x x x x x x x x
Flushing postmarketing, common x x x x x x x x x x x x x x x x x x x
Hiccups postmarketing, uncommon x x x x x x x x x x x x x x x x x x x
Hypersensitivity postmarketing x x x x x x x x x x x x x x x x x
Type I hypersensitivity rare x x x x x
Laryngeal oedema postmarketing x x x x x x x x x x x x x x x x x
Laryngospasm postmarketing x x x x x x x x x x x x x x x x x
Mediastinal disorder postmarketing x x x x x
Myocardial infarction postmarketing x x x
Nervous system disorder postmarketing x x x x x
Pain postmarketing, 2.19% 2.93% x x x x x x x x x x
Palpitations postmarketing x x x x x x x x x x x
Shock postmarketing x x x x x x x x x x x x x x
Stevens-Johnson syndrome postmarketing x x x x x
Stridor postmarketing x x x x x x x x x x x x x x x x x
Syncope postmarketing x x x x x x x x x x x
Supraventricular tachycardia postmarketing x x x x x x x x x x x
Torsade de pointes rare x
Tremor postmarketing x x x
Urticaria postmarketing x x x x x x x x x x x x x x x x x
Angiopathy rare x x
Vomiting postmarketing
Hepatic failure postmarketing x x x x x x x x x x x x x x x x x
Oculogyric crisis postmarketing, uncommon x x x x x x x x x x x x x x x x x x x
Ventricular extrasystoles postmarketing x x x x x x x x x x x
Myocardial ischaemia postmarketing x x x
Opisthotonus postmarketing x x x
Orofacial dyskinesia postmarketing x x x
Accommodation disorder postmarketing x x x x x x x x
Blindness transient very rare, postmarketing x x x x x x x x x x x x x x x x x x
Atrioventricular block second degree postmarketing x x x x x x x x x x x
Hepatobiliary disease postmarketing x x x x x
Redness postmarketing x x x x x x x x x
Vision blurred postmarketing x x x x x x x x x x x x
Blindness postmarketing x x x x x
Electrocardiogram ST segment depression postmarketing, uncommon x x x x x x x x x x x x x
Nausea postoperative postmarketing
Injection site burning postmarketing x x x x x x x x
Dystonic reaction postmarketing — 0% - 5% 0% x x x x x x x x x x x x x x x x x x x x
Visual disturbance rare x x x x
Cardio-respiratory arrest postmarketing x x x x x x x x x x x x x x x x
Local reaction postmarketing x x x x x x x x x
Electrocardiogram QT corrected interval prolonged rare x
Lymphocyte transformation test positive postmarketing x x x x x x
Toxic skin eruption very rare
Abdominal pain x x x x
Asthenia x x x
Asthma x
Cough x
Ear disorder x
Rash x x x x x x x x x x x x x x x x x x x
Flatulence x
Gastrointestinal disorder x x
Cardiac disorder x x
Haemorrhage x
Hypokalaemia x x x x x x x x x x x x x x x x x x
Immune system disorder x x
Liver disorder x x x x x x x x x x x x x x x
Sleep disturbance x
Swelling x
Tachycardia x x x x x x x x x x x x x x x x x x
Urinary tract infection x
Aspartate aminotransferase increased x x x
Unspecified disorder of skin and subcutaneous tissue
Anaphylactoid reaction x x x x x x x
Akathisia 0% - 6% 0% x x
Tonic-clonic seizures x x x x x x x x x x x x x x x

Indications

Information about indications was extracted from the indications and usage sections of the labels.

ondansetron

Side effects:14
Source:FDA Structured Product Label

ONDANSETRON

Side effects:34
Source:FDA Structured Product Label

ONDANSETRON

Side effects:39
Source:FDA Structured Product Label

ONDANSETRON / ZOFRAN ODT

Side effects:42
Source:FDA

ONDANSETRON

Side effects:43
Source:FDA Structured Product Label

ONDANSETRON

Side effects:44
Source:FDA Structured Product Label

ONDANSETRON

Side effects:45
Source:FDA Structured Product Label

ONDANSETRON

Side effects:48
Source:FDA Structured Product Label

ONDANSETRON

Side effects:49
Source:FDA Structured Product Label

ONDANSETRON

Side effects:51
Source:FDA Structured Product Label

ONDANSETRON

Side effects:51
Source:FDA Structured Product Label

ONDANSETRON

Side effects:52
Source:FDA Structured Product Label

ONDANSETRON

Side effects:55
Source:FDA Structured Product Label

ONDANSETRON

Side effects:55
Source:FDA Structured Product Label

Ondansetron

Side effects:61
Source:FDA Structured Product Label

Color scheme:

standard – alternative

    100%
    75%
    50%
    10%
    frequent (1% to 100%)
    infrequent (0.1% to 1%)
    rare (<0.1%)
    postmarketing
    0%
    no frequency information
    not found on label